Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06617923 · ClinicalTrials.gov registry record · Phase 2
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
A Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cavity Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT06617923: Recruiting Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cavity Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT06617923 is a Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cavity Cancer that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 18 participants, below the 256-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06617923, a Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cavity Cancer, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.
Primary Outcome
Clinical activity (response frequency) of Senaparib and Temozolomide. The primary endpoint of clinical activity is the objective response rate (ORR) defined as complete response (CR) + partial response (PR). Tumor response is defined by RECIST v 1.1. If a patient fails to respond (or has stable disease), the patient will be defined as a non-responder in the analysis. ORR will be estimated using binomial distribution together with 95% Clopper-Pearson confidence interval.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Senaparib
Study Locations (2)
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Pennsylvania
- University of Pennsylvania/Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
What NCT06617923 shows while recruiting
NCT06617923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 256-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT06617923 reports a single indexed study location in Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06617923 about?
NCT06617923 is a clinical study titled "Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer". This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.
What is the current status of trial NCT06617923?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2025-02-06. Estimated completion is 2029-12.
What conditions does trial NCT06617923 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Ovary Cancer.
What interventions are being tested in trial NCT06617923?
The interventions under investigation include: Temozolomide (DRUG), Senaparib (DRUG).
Who is sponsoring clinical trial NCT06617923?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06617923 being conducted?
This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06617923's enrollment target sits among peer trials
18 78th of 85 higher than 6 of 85 other Fallopian Tube Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fallopian Tube Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI